VERIFIEDMint Companies·13 May 2026neutral

Cipla bets on fast-growing biosimilars market, to steadily add products: CEO

AI Summary

·Cipla plans to add 1-2 biosimilar products annually for the next five years.
·The company is investing in R&D for biosimilars.
·Focus areas include respiratory, peptides, and complex generics for developed markets.